Last reviewed · How we verify

Insulin, regular - act rapid

HaEmek Medical Center, Israel · FDA-approved active Small molecule

Regular insulin binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.

Regular insulin binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when oral agents are insufficient).

At a glance

Generic nameInsulin, regular - act rapid
SponsorHaEmek Medical Center, Israel
Drug classInsulin (short-acting)
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhaseFDA-approved

Mechanism of action

Regular insulin is a short-acting human insulin that mimics endogenous insulin secretion. It binds to insulin receptors on muscle, fat, and liver cells, facilitating glucose transport into cells and promoting glycogen synthesis while inhibiting gluconeogenesis. This results in rapid reduction of blood glucose levels, typically beginning within 30 minutes of injection.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: